JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
JCR Pharmaceuticals Co., Ltd. reported a significant decline in their financial performance for the first half of FY2024, with net sales dropping by 31.4% and a net loss per share compared to the same period last year. Despite maintaining dividend forecasts, the company revealed changes in its subsidiary structure, excluding Mycenax Biotech Inc. from consolidation.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
